ACTU Stock Analysis: Buy, Sell, or Hold?
ACTU - Actuate Therapeutics, Inc. Common stock
$2.25
0.10 (4.65%)
▲
5d:
-7.79%
30d:
-39.84%
90d:
-65.2%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When ACTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACTU shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ACTU shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ACTU is currently trading at $2.25, which is considered oversold relative to its 30-day fair value range of $2.32 to $3.67.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $2.05, while resistance sits at $2.80. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ACTU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.03 (+1064.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $2.05, while resistance sits at $2.80. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ACTU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.03 (+1064.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.32 -
$3.67
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 1064.2% below Wall St target ($25.03)
- CAUTION: Recommendation downgraded due to -7.8% 5-day decline
Fair Price Analysis
30-Day Fair Range
$2.32 -
$3.67
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.05
Resistance Level
$2.80
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.52
Wall Street Target
$25.03
(+1064.2%)
Share & Embed Analysis
Last updated: March 30, 2026 11:55 AM ET
Data refreshes hourly during market hours. Next update: 12:55 PM
Data refreshes hourly during market hours. Next update: 12:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Todd S Thomson
SELL
280000 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
